Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089065 | 0.88 | CFTR (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL27895204 | 0.83 | CFTR (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL19718477 | 0.81 | ALDH1A1 (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL17591685 | 0.81 | CFTR (0.52) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL14392033 | 0.81 | ALDH1A1 (0.43) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL19402426 | 0.80 | KAT2B (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL27672741 | 0.80 | ALDH1A1 (0.43) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL26620706 | 0.78 | ALDH1A1 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL10446411 | 0.78 | CFTR (0.58) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL10236 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2470012-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-0871615-B1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6194581-B1 | FOR TREATMENT OF DYSFUNCTION OF THE CENTRAL OR AUTONOMIC NERVOUS SYSTEMS INCLUDING DEMENTIA, COGNITIVE DISORDERS, NEURODEGENERATIVE DISORDERS, EXTRAPYRAMIDAL DISORDERS, CONVULSIVE DISORDERS, CARDIOVASCULAR DISORDERS, PAIN | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| US-5852041-A | Substituted pyridines useful as modulators of acethylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0871615-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5736560-A | USEFUL IN THE TREATMENT OF ALZHEIMER'S AND PARKINSONS'S DISEASES | SIBIA NEUROSCIENCES, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5686473-A | TREATING PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, DEMENTIA AND PAIN | SIBIA NEUROSCIENCES, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5585388-A | Substituted pyridines useful as modulators of acetylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996031475-A2 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CFTR 1414/4885SLC6A2 553/4885SLC6A4 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.